BlackRock
BMY.RT

BlackRock’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

BlackRock’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,865,451
Closed -$1.29M – 5440
2020
Q4 		$1.29M Sell
1,865,451
-206,785
-10% -$440K ﹤0.01% 4157
2020
Q3 		$4.66M Sell
2,072,236
-12,639
-0.6% -$36.1K ﹤0.01% 3603
2020
Q2 		$7.46M Sell
2,084,875
-50,665
-2% -$183K ﹤0.01% 3357
2020
Q1 		$8.12M Buy
2,135,540
+904,688
+74% +$2.98M ﹤0.01% 3105
2019
Q4 		$3.71M Buy
+1,230,852
New +$3.2M ﹤0.01% 3584

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

BlackRock's BMY.RT Position: Q1 2021 in Review

BlackRock sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,865,451 shares — an estimated $1.29M sold.

BlackRock first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $8.12M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • BlackRock reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • BlackRock sold 1,865,451 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.29M.
  • BlackRock first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • BlackRock's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $8.12M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.